Accessibility Menu
Ocumension Therapeutics logo

Ocumension Therapeutics(SEHK) 1477

Market CapHK$4.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-86%
5 Year-74%
1 Year-42%
1 Month+2%
HK$5.17
-2.45%
-0.13Today
Ocumension Therapeutics last closing stock price
MetricPriceDate
Last closeHKD 5.172026-08-31
Ocumension Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.58%HKD 5.202026-08-24
1 month+2.17%HKD 5.062026-07-31
3 month-11.93%HKD 5.872026-06-02
Year to date-30.14%HKD 7.402025-12-31
1 year-41.98%HKD 8.912025-08-29
3 year-37.41%HKD 8.262023-08-31
5 year-73.76%HKD 19.702021-09-01
Since inception-85.68%HKD 37.002020-07-10

Ocumension Therapeutics Financials at a Glance

Market Cap

HK$4.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥1.22B

Net Income (TTM)

-CN¥427.09M

EPS (TTM)

-HK$0.22

P/E Ratio

-24.62

Dividend

HK$0.00

Beta (Volatility)

-0.08 (Low)

Price

HK$5.17

Volume

149,500

Open

HK$5.30

Previous Close

HK$5.30

Daily Range

HK$5.13 - HK$5.30

52-Week Range

HK$4.04 - HK$10.94

Estimated Earnings Date

Mar 19, 2027

1477 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ocumension Therapeutics

Ocumension Therapeutics is a biotechnology company based in the People's Republic of China, specializing in ophthalmic pharmaceuticals. The company focuses on developing and commercializing innovative therapeutic solutions for various eye conditions, aiming to improve patient outcomes in the field of ophthalmology.

Products and Services
  • Therapeutic solutions for eye disorders such as glaucoma and dry eye syndrome
  • Extensive pipeline with 20 drug assets targeting multiple ophthalmic conditions
  • Research and development initiatives aimed at advancing eye care treatments
Growth Outlook
  • Recent quarterly revenue increased to CNY 510 million, reflecting strong market demand
  • Significant investment in R&D, with expenses reaching CNY 36 million last quarter
  • Expansion plans include targeting new therapeutic areas and enhancing product offerings
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 1.4 billion, indicating robust growth potential
  • Current ratio of 3.70 suggests strong liquidity and financial stability
  • Net income for the latest quarter was CNY -26.5 million, showing ongoing investment in growth
Ocumension Therapeutics operates in a dynamic and growing sector, with a strong focus on addressing unmet medical needs in ophthalmology. The company's commitment to research and development, coupled with a diverse product pipeline, positions it well for future growth. Recent financial performance indicates a solid foundation, with increasing revenues and a healthy liquidity position. As the company continues to innovate and expand its offerings, it remains a noteworthy player in the biotechnology industry.
AI Generated • Aug 3, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

552

CEO

Ye Liu

Website

www.ocumension.com

Headquarters

Suzhou, JS, CN

1477 Financials

Key Financial Metrics (TTM)

Gross Margin

44.87%

Operating Margin

-19.92%

Net Income Margin

-19.75%

Return on Equity

-4.33%

Return on Capital

-4.14%

Return on Assets

-3.88%

Earnings Yield

-4.06%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$4.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

823.01M

Volume

149.50K

Avg. Volume

1.11M

Financials (TTM)

Gross Profit

CN¥585.99M

Operating Income

-CN¥466.64M

EBITDA

-CN¥290.00M

Operating Cash Flow

-CN¥284.12M

Capital Expenditure

-CN¥300.46M

Free Cash Flow

-CN¥584.58M

Cash & ST Invst.

CN¥547.50M

Total Debt

CN¥187.62M

Ocumension Therapeutics Performance Analysis

Ocumension Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 184,847,630173.2%
20232023-12-31CNY 272,235,04247.3%
20242024-12-31CNY 452,454,19966.2%
20252025-12-31CNY 872,338,54292.8%
Ocumension Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3017.5%
Q42024-12-3149.0%
Q22025-06-3017.8%
Q42025-12-3173.6%
Ocumension Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.7443.4%
20232023-12-31CNY -0.65-12.7%
20242024-12-31CNY -0.43-34.2%
20252025-12-31CNY -0.22-48.8%
Ocumension Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3011.5%
Q42024-12-3130.4%
Q22025-06-30-6.3%
Q42025-12-3180.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CN¥510.32M

+257.7%

Gross Profit

CN¥255.28M

+212.6%

Gross Margin

50.02%

N/A

Market Cap

HK$4.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$7.90M

N/A

Employees

552

N/A

Net Income

-CN¥26.50M

+84.5%

EBITDA

CN¥39.88M

+125.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CN¥547.50M

-47.8%

Total Debt

CN¥187.62M

+36.0%

Accounts Receivable

CN¥339.76M

+184.7%

Inventory

CN¥63.94M

+96.9%

Long Term Debt

CN¥125.20M

+2113.2%

Short Term Debt

CN¥62.39M

-52.9%

Return on Assets

-3.88%

N/A

Return on Invested Capital

-4.18%

N/A

Free Cash Flow

-CN¥256.99M

-121.0%

Operating Cash Flow

-CN¥8.82M

+85.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 1477

What is the current price of Ocumension Therapeutics?

Ocumension Therapeutics is trading at HK$5.17 per share.

What is the 52-week range for Ocumension Therapeutics?

Over the past 52 weeks, Ocumension Therapeutics has traded between HK$4.04 and HK$10.94.

How much debt does Ocumension Therapeutics have?

As of the most recent reporting period, Ocumension Therapeutics reported total debt of CN¥208.88M.

How much cash does Ocumension Therapeutics have on hand?

Ocumension Therapeutics reported CN¥420.42M in cash and cash equivalents in its most recent financial results.

What is Ocumension Therapeutics’s dividend yield?

Ocumension Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services